Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
Дата публикации: 24-06-2026 07:06:00

Evidence for efficacy is based on the results from the TROPION-Breast02 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
2EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
3EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
4EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
5Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
6New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
7أدوية جديدة تحل محل العلاج الكيميائي لسرطان الثدي العدواني5725-06-2026
8Why FDA approval for vepdegestrant is a major shift in cancer therapy8706-07-2026
9В ФМБА завершили доклиническое исследование нового противоопухолевого препарата0004-03-2025
10Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer0722-08-2024

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.esmo.org.